De omzetaandelen zijn schattingen voor year ended December 31, 2025, geen cijfers uit een ingediend rapport.
Mounjaro
A medicine used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Zepbound
A medicine for adults with obesity, or overweight with a weight-related health condition. It is also approved for certain adults with obesity and moderate to severe sleep apnea.
Foundayo (orforglipron)
An oral medicine approved in the United States for obesity. Lilly has also submitted it for review as a treatment for type 2 diabetes.
Verzenio
A medicine used alone or with hormone treatment for certain adults with hormone receptor-positive breast cancer.
Jardiance
A medicine used for type 2 diabetes and to reduce certain risks related to heart failure and chronic kidney disease. Lilly markets it in collaboration with Boehringer Ingelheim.
Trulicity
A medicine for type 2 diabetes in adults and some children, and to reduce the risk of certain heart problems in some adults with type 2 diabetes.
Lilly researches, develops, manufactures, and sells human medicines in the United States and around the world. Its medicines treat conditions including type 2 diabetes, obesity, cancer, inflammatory diseases, migraine, and Alzheimer's disease. It also works with other companies on research, development, and marketing of some medicines.
Gebouwd uit de eigen deponeringen van ELI Lilly & Co bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
US$ 1.444,80+1,0%slot 13 nov
Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 29 oktober 2026
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
Bedrijfsprognose: omzet van US$ 91B tot US$ 92B voor Boekjaar 2026 — 40,4% hoger dan een jaar eerder
Just reported
From ELI Lilly's results release of 29 oktober 2026; its quarterly report has since been filed.
Actual
US$ 24,4B
+39% y/y
+6,2% q/q
Guided
—
No guide given
Actual
US$ 7,22
+16% y/y
-9,1% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes ELI Lilly is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 41 kwartalen van de cijferhistorie van ELI Lilly & Co. De andere 39 lopen terug tot oktober 2016.
